ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2071

Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset

praggya yaadav1, Maria Rosa Pellico2, Anne-Marie Russell3, Aviya Lanis4, Elena Nikiphorou5, Ioannis Parodis6, Sreoshy Saha7, Manali Sarkar8, Jasmine Parihar9, Laura Andreoli10, Vikas Agarwal11 and Latika Gupta12, and COVAD Steering Committee, COVAD Study Group, 1Maharashtra Institute of Medical Sciences and Research, Latur, Aurangabad, India, 2University of Milan, Milan, Italy, 3Birmingham Regional Interstitial Lung Disease Service, University Hospitals Birmingham NHS Trust and Faculty of Life Sciences, University of Exeter, Exeter, UK, Birmingham, United Kingdom, 4Seattle Children's Hospital, Seattle, WA, 5King's College London, London, United Kingdom, 6Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 7Mymensingh Medical College, Mymensingh, Bangladesh, 8MGM Medical College, Navi Mumbai, Maharashtra, India, 9All India Institute of Medical Science, New Delhi, Delhi, India, 10University of Brescia, Brescia, Italy, 11Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 12Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Disease Activity, exercise, mental health, Myopathies, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Self-efficacy is crucial for chronic disease management. Given the increasing prevalence of chronic diseases, encouraging patients to actively manage their disease may be an effective strategy for decreasing morbidity and mortality, reducing healthcare costs, and enhancing quality of life (QoL). This study explores how individuals with idiopathic inflammatory myopathies (IIMs) experience work, daily activities, and social interactions while managing IIM symptoms. We observed the association between s elf-efficacy and education, disease management, QoL, pain, and fatigue among IIM patients, utilizing data from Collating the Voice of People with Autoimmune Diseases (COVAD)-3 study.

Methods: COVAD-3 is a global patient-reported survey collecting data on health outcomes using validated tools. Data was extracted in May 2024; IIM patients were assessed for self-efficacy using the Self-Efficacy in Managing Chronic Disease (SEMCD) scale. Data was categorized into two groups based on scores. Patients scoring above the 67th percentile (SEMCD 6.3) were classified as having high self-efficacy and those below the 33rd percentile (SEMCD 4.6) as low self-efficacy [Fig 1 A]. Demographic and clinical characteristics were compared between the two groups using descriptive statistics, Pearson’s correlation, and appropriate statistical tests (χ2, Mann-Whitney, or t-test).

Results: Of 4,052 responses, 314 IIM patients who successfully completed SEMCD (F 228 72.6%; median SEMCD score 5.56 [range 1 -10]) were included [Fig 1B]. Based on scores, patients were stratified: 95 showed low self-efficacy scores (SEMCD < 4.3) and 110 showed high self-efficacy in managing IIMs (SEMCD >6.3). The high self-efficacy group exhibited higher satisfaction with life scores (p = 0.015), significantly longer disease duration (p = 0.003), and lower Visual Analog Scale (VAS)-fatigue scores (p = 0.009) than the low self-efficacy group. Physical function, measured by PROMIS Physical SF4a, was significantly higher in the high self-efficacy group (p = 0.021) [Fig 1C]. Furthermore, a greater proportion of individuals in the high self-efficacy group exercised regularly (p < 0.001). Interestingly, no significant difference in education level or patient trust in health provider was found with self-efficacy in IIMs [Table 1-2]. Additionally, no significant statistical difference in self-efficacy was found across IIM subgroups.

Conclusion: High self-efficacy may contribute to better physical and mental health, life satisfaction, and lower disease activity, fatigue, and pain. This underscores the importance of self-efficacy in influencing physical and psychological well-being of patients with IIMs. Healthcare providers should identify individual factors that influence self-management ability and develop strategies to facilitate communication and patient education, as this could reduce complications, healthcare costs, improve health outcomes and QoL. Thus, multidisciplinary pathways to coach patients and support group leaders can advance patient empowerment and enhance care of our patients.

Supporting image 1

Figure 1
A: Characteristics of the Self-Efficacy for Managing Chronic Diseases Scale
B: Work flow chart depicting the inclusion of participant responses
C: Correlation of Variables with Self-Efficacy

Supporting image 2

Table 1: Correlation of Self-Efficacy with Patient Demographics

Supporting image 3

Table 2: Correlation of Variables with Self-Efficacy


Disclosures: p. yaadav: None; M. Pellico: None; A. Russell: None; A. Lanis: None; E. Nikiphorou: AbbVie, 1, 6, Alfasigma, 1, 6, Fresenius Kabi, 1, 6, Galapagos, 1, 6, Gilead, 1, 6, Lilly, 1, 5, 6, Pfizer, 1, 5, 6, UCB, 1, 6; I. Parodis: Amgen, 5, 6, AstraZeneca, 1, 2, 6, Aurinia, 1, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, Eli Lilly, 5, GlaxoSmithKlein(GSK), 1, 2, 5, 6, Janssen, 2, 6, Novartis, 1, 2, Otsuka Pharma, 1, 2, 5, 6, Roche, 2, 5, 6; S. Saha: None; M. Sarkar: None; J. Parihar: None; L. Andreoli: Pfizer, 2, UCB, 2; V. Agarwal: None; L. Gupta: None.

To cite this abstract in AMA style:

yaadav p, Pellico M, Russell A, Lanis A, Nikiphorou E, Parodis I, Saha S, Sarkar M, Parihar J, Andreoli L, Agarwal V, Gupta L. Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/self-efficacy-contributes-to-better-health-outcomes-in-patients-of-idiopathic-inflammatory-myopathies-insights-from-the-covad-3-dataset/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/self-efficacy-contributes-to-better-health-outcomes-in-patients-of-idiopathic-inflammatory-myopathies-insights-from-the-covad-3-dataset/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology